PDS Biotechnology Corp Long-Term Debt, Maturity, Year Three
PDS Biotechnology Corp (PDSB) had Long-Term Debt, Maturity, Year Three of $7.11 million as of 2018-03-31, per its 10-Q filed 2018-05-01.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree · last filed 2018-05-01
- 2018-03-31: Long-Term Debt, Maturity, Year Three $7.11M.
- 2017-12-31: Long-Term Debt, Maturity, Year Three $7.10M.
- 2017-09-30: Long-Term Debt, Maturity, Year Three $10.29M.
- 2017-06-30: Long-Term Debt, Maturity, Year Three $10.29M.
| Period end | Long-Term Debt, Maturity, Year Three |
|---|---|
| 2018-03-31 | $7.11M 10-Q · filed 2018-05-01 |
| 2017-12-31 | $7.10M 10-K · filed 2018-03-01 |
| 2017-09-30 | $10.29M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $10.29M 10-Q · filed 2017-08-01 |
| 2017-03-31 | $7.72M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $7.72M 10-K · filed 2017-03-02 |
| 2016-09-30 | $5.91M 10-Q · filed 2016-11-01 |
| 2016-06-30 | $682.00K 10-Q · filed 2016-08-03 |
| 2016-03-31 | $682.00K 10-Q · filed 2016-05-03 |
| 2015-12-31 | $682.00K 10-K · filed 2016-03-08 |
| 2015-09-30 | $2.51M 10-Q · filed 2015-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |